1. Home
  2. CTKB vs RLMD Comparison

CTKB vs RLMD Comparison

Compare CTKB & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

HOLD

Current Price

$5.64

Market Cap

541.1M

Sector

Health Care

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$3.83

Market Cap

461.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTKB
RLMD
Founded
1990
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
541.1M
461.9M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
CTKB
RLMD
Price
$5.64
$3.83
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
$5.63
★ $12.40
AVG Volume (30 Days)
1.1M
★ 1.1M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 45.28
EPS
★ N/A
N/A
Revenue
★ $193,015,000.00
$13,070.00
Revenue This Year
$5.42
N/A
Revenue Next Year
$7.03
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
17.67
★ 154.83
52 Week Low
$3.28
$1.78
52 Week High
$6.18
$8.00

Technical Indicators

Market Signals
Indicator
CTKB
RLMD
Relative Strength Index (RSI) 73.49 34.70
Support Level $4.17 $3.34
Resistance Level $6.04 $4.51
Average True Range (ATR) 0.24 0.23
MACD 0.09 -0.02
Stochastic Oscillator 88.64 21.21

Price Performance

Historical Comparison
CTKB
RLMD

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: